

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



December 18, 2023

**National Stock Exchange of India Limited**  
**Script Symbol: SUNPHARMA**

**BSE Limited**  
**Script Code: 524715**

**Sub: Intimation of agreement to acquire stake in Lyndra Therapeutics, Inc.**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), This is to inform you that Sun Pharmaceutical Industries Limited (which includes its subsidiaries and/or associate companies) ["Company"], has entered into agreement to acquire stake ~16.7% shares on fully diluted basis, in Lyndra Therapeutics, Inc., a company based in Massachusetts, engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies.

The particulars of the disclosure required as per Listing Regulations are provided in Annexure A as enclosed herewith.

This is for your information and dissemination.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.

Tel. : (91-22) 4324 4324

Fax : (91-22) 4324 4343

Website: [www.sunpharma.com](http://www.sunpharma.com)

Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)

CIN: L24230GJ1993PLC019050

**Annexure A****Disclosure under sub-para (1) i.e. Acquisition(s) (including agreement to acquire) of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Information								
1	Name of the target entity, details in brief such as size, turnover etc.;	Lyndra Therapeutics, Inc., a company based in Massachusetts, having its registered office at Watertown, MA. The Company is in the business of developing novel delivery technology for long-acting oral (LAO) therapies.								
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.								
3	Industry to which the entity being acquired belongs;	Pharmaceutical Delivery Technology								
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Strategic investment to support development of innovative pharmaceutical delivery technologies and get access to the technology for certain molecules and territories								
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable								
6	Indicative time period for completion of the acquisition;	By the end of December 2023, subject to certain conditions.								
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration								
8	Cost of acquisition or the price at which the shares are acquired;	USD 30 mn.								
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	~16.7% shares on fully diluted basis								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>The company is engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies.</p> <p>The company was incorporated on 14<sup>th</sup> January, 2015</p> <p>The revenue from operations for previous three years is as follows,</p> <table border="1"> <thead> <tr> <th>FY (1 Jan to 31 Dec)</th> <th>Turnover (in USD mn)</th> </tr> </thead> <tbody> <tr> <td>2022</td> <td>10.7</td> </tr> <tr> <td>2021</td> <td>13.1</td> </tr> <tr> <td>2020</td> <td>25.6</td> </tr> </tbody> </table>	FY (1 Jan to 31 Dec)	Turnover (in USD mn)	2022	10.7	2021	13.1	2020	25.6
FY (1 Jan to 31 Dec)	Turnover (in USD mn)									
2022	10.7									
2021	13.1									
2020	25.6									

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.